Waking up from the DREAM of preventing diabetes with drugs

The current epidemic of diabetes makes a drug to prevent it attractive. But despite promotion of recent research evidence, Victor Montori, William Isley, and Gordon Guyatt argue that we are not there yet

[1]  M. Laakso,et al.  Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial , 2006, The Lancet.

[2]  D. D. de Ridder,et al.  Psychological Outcomes of Patients With Screen-Detected Type 2 Diabetes , 2006, Diabetes Care.

[3]  B. Howard,et al.  Effects of Diet and Exercise in Preventing NIDDM in People With Impaired Glucose Tolerance: The Da Qing IGT and Diabetes Study , 1997, Diabetes Care.

[4]  S. Cummings,et al.  Thiazolidinedione use and bone loss in older diabetic adults. , 2006, The Journal of clinical endocrinology and metabolism.

[5]  C. Kendall,et al.  Rosiglitazone (Avandia) and macular edema , 2006, Canadian Medical Association Journal.

[6]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[7]  S. Wild,et al.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.

[8]  Who needs health care—the well or the sick? , 2005, BMJ : British Medical Journal.

[9]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[10]  J. Tuomilehto,et al.  Glucose lowering and diabetes prevention: are they the same? , 2006, The Lancet.

[11]  G. Guyatt,et al.  Validity of composite end points in clinical trials , 2005, BMJ : British Medical Journal.

[12]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[13]  T. Buchanan,et al.  Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. , 2002, Diabetes.

[14]  B. Zinman,et al.  Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. , 2006, The New England journal of medicine.

[15]  Krystal L. Edwards,et al.  Effect of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Blockers on the Rate of New‐Onset Diabetes Mellitus: A Review and Pooled Analysis , 2006, Pharmacotherapy.

[16]  S. Fowler,et al.  Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. , 2005, Diabetes.

[17]  R. Moynihan,et al.  On music , 2002, BMJ : British Medical Journal.

[18]  Gordon H Guyatt,et al.  Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials , 2007, BMJ : British Medical Journal.

[19]  Gordon H Guyatt,et al.  Users' guide to detecting misleading claims in clinical research reports , 2004, BMJ : British Medical Journal.

[20]  S. Yusuf,et al.  Effect of ramipril on the incidence of diabetes. , 2006, The New England journal of medicine.

[21]  Colin Mathers,et al.  The burden of mortality attributable to diabetes: realistic estimates for the year 2000. , 2005, Diabetes care.

[22]  F. McAlister,et al.  A systematic review of drug therapy to delay or prevent type 2 diabetes. , 2005, Diabetes care.